Pfizer and KineMed, Inc. have entered a non-exclusive research collaboration to advance novel approaches in metabolic disease, namely Type II Diabetes. KineMed will use its Dynamic Proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways. “We are delighted to be collaborating with Pfizer in taking novel and innovative approaches, by targeting disease pathways that have previously remained undeveloped as drug targets,” said Dr. Scott Turner, ex...